• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by GE HealthCare Technologies Inc.

    3/26/26 6:37:20 PM ET
    $GEHC
    Medical Electronics
    Health Care
    Get the next $GEHC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    GE HealthCare Technologies Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    36266G107

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    36266G107


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    GE HealthCare Technologies Inc
    (b)Address of issuer's principal executive offices:

    500 W Monroe Street, 16th Floor, Chicago, IL, 60661
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/26/2026
    Get the next $GEHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GEHC

    DatePrice TargetRatingAnalyst
    1/15/2026$77.00Neutral → Sell
    UBS
    10/13/2025$86.00Equal Weight
    Barclays
    10/7/2025$83.00Buy → Neutral
    Citigroup
    5/5/2025$73.00Sell → Neutral
    UBS
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    9/26/2024$84.00 → $74.00Neutral → Sell
    UBS
    9/18/2024$100.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $GEHC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by GE HealthCare Technologies Inc.

    SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    3/26/26 6:37:20 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form DEFA14A filed by GE HealthCare Technologies Inc.

    DEFA14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

    3/19/26 7:03:57 AM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form DEF 14A filed by GE HealthCare Technologies Inc.

    DEF 14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

    3/19/26 7:02:54 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe

    COMPASS is one of the largest public‑private partnerships under the European Union's (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (NASDAQ:GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a t

    3/26/26 8:30:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare to showcase comprehensive cardiology portfolio at ACC.26, including its latest AI-enabled imaging technologies, advanced software solutions, and key collaborations

    The company will highlight the newly U.S. FDA 510(k) cleared Photonova Spectra photon-counting CT system, ReadyFix fleet management solution enabled to work with MAC VU360 resting ECG workstations, and a new collaboration to advance interventional cardiology At ACC.26, GE HealthCare (NASDAQ:GEHC) will showcase some of its boldest ideas yet that support clinicians across the cardiology care pathway - from diagnosis to treatment to procedural guidance and monitoring. Its latest cardiology innovations, featuring advancements within diagnostic cardiology, CT, image guiding solutions, ultrasound, cloud, and software solutions, are helping clinicians deliver critical precision care throughout

    3/25/26 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare's Photonova Spectra photon-counting CT receives FDA clearance

    FDA clearance quickly follows Photonova Spectra's debut at the Radiological Society of North America (RSNA) 2025 Annual Meeting, marking rapid momentum for GE HealthCare's innovative photon-counting CT technology Photonova Spectra introduces the next generation of spectral photon-counting CT technology with 8‑bin energy resolution, powered by GE HealthCare's proprietary Deep Silicon detector technology and a one‑scan universal workflow designed to boost efficiency and reduce complexity across a wide range of CT exams Photonova Spectra is a result of the company's $5.1 billion innovation investment, leading to a wave of transformational products across the portfolio which combined are

    3/23/26 9:59:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GE HealthCare downgraded by UBS with a new price target

    UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $77.00

    1/15/26 8:32:16 AM ET
    $GEHC
    Medical Electronics
    Health Care

    Barclays initiated coverage on GE HealthCare with a new price target

    Barclays initiated coverage of GE HealthCare with a rating of Equal Weight and set a new price target of $86.00

    10/13/25 8:53:16 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare downgraded by Citigroup with a new price target

    Citigroup downgraded GE HealthCare from Buy to Neutral and set a new price target of $83.00

    10/7/25 8:57:17 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jimenez Frank R bought $100,624 worth of shares (1,315 units at $76.52), increasing direct ownership by 2% to 75,796 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/2/24 6:00:38 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lobo Kevin was granted 777 shares (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    3/17/26 4:08:18 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form 3 filed by new insider Lobo Kevin

    3 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    3/17/26 4:06:05 PM ET
    $GEHC
    Medical Electronics
    Health Care

    CEO, Patient Care Solutions Bankes Jeannette was granted 6,861 shares, increasing direct ownership by 19% to 43,892 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    3/4/26 4:27:18 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/12/24 12:53:28 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    10/22/24 4:16:16 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by GE HealthCare Technologies Inc. (Amendment)

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    4/2/24 4:07:29 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Leadership Updates

    Live Leadership Updates

    View All

    GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

    GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

    3/17/26 9:00:00 AM ET
    $GEHC
    $SYK
    Medical Electronics
    Health Care
    Medical/Dental Instruments

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

    GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

    4/9/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Financials

    Live finance-specific insights

    View All

    GE HealthCare completes Intelerad acquisition – accelerating shift to cloud-first enterprise solutions to deliver precision care

    Expands GE HealthCare's enterprise imaging footprint by delivering comprehensive, end‑to‑end solutions across ambulatory, teleradiology, and hospital care settings Advances GE HealthCare's D3 strategy by accelerating the development of disease‑focused smart devices and solutions enabled by digital (cloud and software) and artificial intelligence (AI) capabilities Enhances a fully connected, cloud‑first imaging ecosystem with an expanded GE HealthCare portfolio of AI, digital tools, and SaaS offerings designed to improve clinical operations Tuck‑in acquisition expected to strengthen the Imaging portfolio, increase recurring revenue mix, and support sustainable top‑line growth and p

    3/18/26 4:00:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare announces cash dividend for first quarter of 2026

    The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2026 payable on May 15, 2026, to all shareholders of record as of April 3, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patie

    2/12/26 6:11:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare reports fourth quarter and full year 2025 financial results

    Company exceeds topline and earnings per share expectations; demonstrates operational resilience Fourth quarter 2025 highlights(1) Revenue growth of 7.1%, including Organic revenue growth* of 4.8%, driven primarily by the U.S. and Europe, the Middle East and Africa (EMEA) Net income margin of 10.3% and Adjusted earnings before interest and taxes (EBIT) margin* of 16.7% Diluted earnings per share (EPS) of $1.29 and Adjusted EPS* of $1.44 Cash flow from operating activities of $1.0 billion and Free cash flow* of $916 million Full year 2025 highlights(1) Revenue growth of 4.8%, including Organic revenue growth* of 3.5% Organic orders growth of 5.2% Net income margin o

    2/4/26 6:20:00 AM ET
    $GEHC
    Medical Electronics
    Health Care